PMID- 35266068
OWN - NLM
STAT- MEDLINE
DCOM- 20220328
LR  - 20220401
IS  - 1568-5608 (Electronic)
IS  - 0925-4692 (Linking)
VI  - 30
IP  - 2
DP  - 2022 Apr
TI  - Repurposing monoamine oxidase inhibitors (MAOI) for the treatment of rheumatoid 
      arthritis possibly through modulating reactive oxidative stress mediated 
      inflammatory cytokines.
PG  - 453-463
LID - 10.1007/s10787-022-00945-9 [doi]
AB  - Monoamine oxidase inhibitors (MAOI) are presently used to treat depression, 
      parkinsonian, and other psychiatric disorders. The present study was aimed to 
      repurpose the use of MOAI in Rheumatoid Arthritis (RA). The animal model of RA 
      was developed using collagen type II (CII) in Freund's complete adjuvant (FCA) 
      followed by lipopolysaccharide (LPS) and a booster dose of CII in FCA. The effect 
      of MAOI, Selegiline was evaluated whereas the indicators like paw thickness, 
      arthritic score, and the splenic index were measured and compared with the 
      standard drug Methotrexate. Further to explore the molecular mechanism, the 
      expression of serum inflammatory cytokines (IL-6 and TNF-alpha), radiographical and 
      histopathological study of hind paw were also checked and analyzed. Treatment 
      with MAOI, Selegiline not only reduced the paw thickness, arthritic score, and 
      the splenic index, but also greatly improved the inflammatory biochemical and 
      hematologic parameters and improved the arthritis score. The serum level of IL-6 
      and TNF-alpha are considerably decreased dose dependently, however, the notable 
      significant effect (**p < 0.01) observed at concentration of 30 mg/kg b.w. when 
      the RA animals treated by Selegiline. Collectively, Selegiline improved the 
      progression of RA possibly via decreased catecholamine breakdown at synovial 
      fluid resulting decrease hydrogen peroxide (H(2)O(2)) generation and inhibition 
      of pro-inflammatory cytokines in situ. Thus, the finding support and indicate the 
      repurposing of MAOI for the treatment of RA meriting further studies on synovial 
      monoamine oxidase as a new therapeutic target to design a new drug for RA.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Sur, Debjeet
AU  - Sur D
AUID- ORCID: 0000-0001-5525-5156
AD  - Division of Pharmacology, Guru Nanak Institute of Pharmaceutical Science & 
      Technology, Sodepur, Kolkata, 700114, India. debjeet24@gmail.com.
AD  - Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata, 
      700109, India. debjeet24@gmail.com.
FAU - Dutta, Arpan
AU  - Dutta A
AD  - Division of Pharmacology, Guru Nanak Institute of Pharmaceutical Science & 
      Technology, Sodepur, Kolkata, 700114, India.
FAU - Mondal, Chaitali
AU  - Mondal C
AD  - TCG Life Science (Chembiotek) Pvt. Ltd, Sector V, Salt Lake Electronic Complex, 
      Kolkata, 700091, India.
FAU - Banerjee, Apurba
AU  - Banerjee A
AD  - TCG Life Science (Chembiotek) Pvt. Ltd, Sector V, Salt Lake Electronic Complex, 
      Kolkata, 700091, India.
FAU - Haldar, Pallab Kanti
AU  - Haldar PK
AD  - Department of Pharmaceutical Technology, Jadavpur University, Kolkata, 700032, 
      India.
FAU - Maji, Himangshu Sekhar
AU  - Maji HS
AD  - Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata, 
      700109, India.
FAU - Bala, Asis
AU  - Bala A
AD  - Division of Pharmacology, Guru Nanak Institute of Pharmaceutical Science & 
      Technology, Sodepur, Kolkata, 700114, India.
LA  - eng
PT  - Journal Article
DEP - 20220310
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - 0 (Cytokines)
RN  - 0 (Monoamine Oxidase Inhibitors)
RN  - BBX060AN9V (Hydrogen Peroxide)
SB  - IM
MH  - Animals
MH  - *Arthritis, Experimental/metabolism
MH  - *Arthritis, Rheumatoid/drug therapy/metabolism
MH  - Cytokines/metabolism
MH  - Drug Repositioning
MH  - Humans
MH  - Hydrogen Peroxide/pharmacology
MH  - Monoamine Oxidase Inhibitors/pharmacology/therapeutic use
MH  - Oxidative Stress
MH  - Rats
MH  - Rats, Wistar
OTO - NOTNLM
OT  - Cytokine
OT  - Drug repurposing
OT  - Monoaminoxidase inhibitor
OT  - Reactive oxygen species
OT  - Rheumatoid arthritis
EDAT- 2022/03/11 06:00
MHDA- 2022/03/29 06:00
CRDT- 2022/03/10 05:48
PHST- 2021/11/23 00:00 [received]
PHST- 2022/02/14 00:00 [accepted]
PHST- 2022/03/11 06:00 [pubmed]
PHST- 2022/03/29 06:00 [medline]
PHST- 2022/03/10 05:48 [entrez]
AID - 10.1007/s10787-022-00945-9 [pii]
AID - 10.1007/s10787-022-00945-9 [doi]
PST - ppublish
SO  - Inflammopharmacology. 2022 Apr;30(2):453-463. doi: 10.1007/s10787-022-00945-9. 
      Epub 2022 Mar 10.